Cargando…

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer

Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after showing initial durable response. This is a case of systemic nocardiosis that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Mihong, Lee, Youngjoo, Hwang, Sang Hyun, Lee, Jin Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286786/ https://www.ncbi.nlm.nih.gov/pubmed/25580145 http://dx.doi.org/10.4046/trd.2014.77.6.271

Ejemplares similares

Pulmonary nocardiosis caused by Nocardia exalbida mimicking lung cancer
por: Miyaoka, Chika, et al.
Publicado: (2019)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations
por: Choi, Seul-Ki, et al.
Publicado: (2022)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012)

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report
por: Kok, Victor C., et al.
Publicado: (2021)

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
por: Li, Xiao-Qiu, et al.
Publicado: (2016)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
por: L’Hostis, Adèle, et al.
Publicado: (2023)

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2021)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2016)

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
por: Han, Ji-Youn, et al.
Publicado: (2017)

3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases
por: Lee, Jin-Young, et al.
Publicado: (2023)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
por: Ma, Lichun, et al.
Publicado: (2015)

Eosinophilic Enteritis Flare-Up Mimicking Acute Gastroenteritis: A Rare Case
por: Veer, Maha, et al.
Publicado: (2023)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
por: Karachaliou, Niki, et al.
Publicado: (2020)

Picropodophyllotoxin Inhibits Cell Growth and Induces Apoptosis in Gefitinib-Resistant Non-Small Lung Cancer Cells by Dual-Targeting EGFR and MET
por: Lee, Jin-Young, et al.
Publicado: (2023)

Nocardiosis mimicking lung cancer in a heart transplant patient with end-stage renal disease
por: Deterding, Lea, et al.
Publicado: (2020)

Primary Cutaneous Nocardiosis: A Rare Presentation of Nocardiosis
por: Tariq, Ezza Fatima, et al.
Publicado: (2019)

Reactive cutaneous cytophagocytosis in nocardiosis.
por: Kim, Chi-Yeon, et al.
Publicado: (2002)

Primary Cutaneous Nocardiosis Caused by Nocardia takedensis
por: Lee, Taek Geun, et al.
Publicado: (2017)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
por: Kuriyama, Yuka, et al.
Publicado: (2013)

Orbital nocardiosis
por: Rath, Suryasnata, et al.
Publicado: (2011)

Cerebral nocardiosis
por: Baldawa, Sachin, et al.
Publicado: (2014)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation
por: Cho, Jung Hee, et al.
Publicado: (2018)

Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Kwon, Byoung Soo, et al.
Publicado: (2017)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
por: Jiang, Ye, et al.
Publicado: (2018)

Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
por: Xu, Chuncao, et al.
Publicado: (2021)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase–Low Squamous Cell Lung Cancer
por: Choi, Mihong, et al.
Publicado: (2021)

Nocardiosis incognito: Primary cutaneous nocardiosis with extension to myositis and pleural infection
por: Nguyen, Nhan M., et al.
Publicado: (2017)

Drug-Like Small Molecule HSP27 Functional Inhibitor Sensitizes Lung Cancer Cells to Gefitinib or Cisplatin by Inducing Altered Cross-Linked Hsp27 Dimers
por: Yoo, Hawon, et al.
Publicado: (2021)

Case series: Nocardiosis of the brain and lungs
por: Sud, Seema, et al.
Publicado: (2008)

Miliary tuberculosis mimicking systemic lupus erythematosus flare
por: Elzein, Fatehi, et al.
Publicado: (2018)

Kaposi Sarcoma Mimicking Acute Flare of Ulcerative Colitis
por: Kumar, Vivek, et al.
Publicado: (2017)

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study
por: Hou, Xue, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rfcsq3ot5viev0emt8do5bet2q